| Heading: |
Clozapine |
| Question ID: |
1758603 |
| UIN: |
26370 |
| House: |
Commons |
| Date tabled: |
2025-01-24 |
| Asking Member ID: |
5040 |
| Asking Member display name: |
Liz Jarvis
|
| Asking Member handle: |
lizjarvisuk
|
| Asking Member Twitter reference: |
@lizjarvisuk
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the (a) efficacy of and (b) adequacy of the provision of Clozapine. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-02-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Clozapine is licenced by the Medicines and Healthcare products Regulatory Agency (MHRA). Products are licenced by the MHRA where the benefit-risk assessment has been found to be positive in relation to quality, safety, and efficacy. Clozapine is marketed ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |